FDA issues EUA for GSK-Vir COVID-19 mAb treatment

By The Science Advisory Board staff writers

May 27, 2021 -- The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab from GlaxoSmithKline (GSK) and Vir Biotechnology. Sotrovimab is a treatment for mild to moderate COVID-19 in adults and pediatric patients over 12 years of age.

The patients must have positive results of direct SARS-CoV-2 viral testing and must be at high risk for progression to severe COVID-19, the agency said. The FDA will continue to evaluate the investigational treatment.

GSK submitted data from a phase I/II/III randomized, double-blind, placebo-controlled clinical trial in 583 nonhospitalized adults with mild to moderate COVID-19 symptoms and a positive SARS-CoV-2 test result. In these studies, 291 patients received sotrovimab and 292 received a placebo within five days of onset of COVID-19 symptoms. Hospitalization or death occurred in 7% patients who received a placebo compared to 1% patients treated with sotrovimab, an 85% reduction.

Sotrovimab, developed by GSK and Vir Biotechnology, is an mAb that is specifically directed against the spike protein of SARS-CoV-2 and is designed to block attachment of the virus and its entry into human cells. The FDA specified that sotrovimab be distributed and administered intravenously as a 500-mg single dose.

EMA gives positive nod to GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology today announced that the European Medicines Agency's (EMA) Committee for Human Medicinal Products has issued...
GSK, Vir file EUA submission for COVID-19 mAb treatment
GlaxoSmithKline (GSK) and Vir Biotechnology filed an emergency use authorization (EUA) application with the U.S. Food and Drug Administration for VIR-7831...
Vir, GSK prepare to submit anti-COVID-19 mAb EUA
Vir Biotechnology and GlaxoSmithKline (GSK) are moving ahead with regulatory submission of their COVID-19 monoclonal antibody (mAb), VIR-7831, after a...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter